Jason Hall joined Mundipharma EDO in November 2018 as Global Head of Knowledge Management. Based in the Basel office, he is an IT professional specialized in solution delivery for the Pharma industry’s research and development, product strategy, commercial operations and communications departments. With a Diploma in Computer Science with Distinction from the University of Cambridge combined with over 18 years’ industry experience, Jason entered the biotech industry with Roche, gaining insights and expertise in areas such as stakeholder management, vendor management, information architecture design, security management, business process management and systems integration.
Alberto Bardelli studied Biological Sciences at the University of Turin, graduating cum laude with an honourable mention. After graduation he moved to the Ludwig Institute for Cancer Research in London where he obtained a PhD in Biochemistry and Molecular Biology from the University College London (UCL). He is a molecular geneticist and expert in the field of personalized therapies, and currently directs the IFOM Genomics of Cancer and Targeted Therapies program at the Institute for Cancer Research and Treatment in Candiolo, near Turin. Since 2005 Professor Bardelli has been an Associate Professor in the Department of Oncology, Medical School, University of Turin.
Professor Bardelli has authored more than 140 scientific articles, including 100 as an independent investigator. Discoveries from his group have led to the development of diagnostic tests, currently in clinical use, based on the genetic profiles of individual tumours. These discoveries represent the first example of personalized therapies for colorectal cancer patients, as was recently reported in Nature, JAMA, and Lancet Oncology.
John de Groot is Professor, and Chairman ad interim, in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center. He is an expert in the fields of glioma angiogenesis and molecularly targeted therapy. Professor de Groot completed his medical education at The University of Texas Medical Branch at Galveston, and pursued internship and residency at Johns Hopkins School of Medicine. Following a clinical fellowship at MD Anderson, he joined the faculty in 2004.
Professor de Groot has served as the principal investigator (PI) or co-investigator on multiple funded National Cancer Institute, foundation, and industry-sponsored grants. He is the PI of numerous clinical trials involving novel agents being tested in patients with glioblastoma and is a leader of MD Anderson’s Glioblastoma Moon Shot. As the previous fellowship program director and current interim Chair of Neuro-Oncology, he is also helping develop the next generation of neuro-oncologists. He has over one hundred peer reviewed articles, and is or has been a peer reviewer for 23 scientific journals, both national and international, and is a member of four editorial review boards.
Dr. Kummar is Professor of Medicine and Director of the Phase I Clinical Research and Translational Oncology Programs at Stanford University. Prior to joining Stanford in 2015, Dr. Kummar served as the Head of Early Clinical Trials Development in the Office of the Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland. Her research interests focus on developing novel therapies for cancer, conducting pharmacokinetic and pharmacodynamic driven first-in-human trials. The clinical studies integrate genomics, imaging, and laboratory correlates into early phase trials. She serves on multiple national and international scientific committees and has published >125 papers in peer review journals.
Bob Lutz is Principal Consultant at Crescendo Biopharma Consulting and has extensive experience in the development of antibody-based therapeutics. He has been providing C-level support to emerging biotech and pharma since 2015. Prior to initiating his consulting practice, Bob held various R&D roles over 23 years at ImmunoGen, Inc, where he was Vice President of Translational Research and Development, with responsibility for all early stage antibody drug conjugate (ADC) development programs. He was also a member of ImmunoGen’s portfolio research committee, served on numerous alliance committees supporting the R&D programs of ImmunoGen’s licensed partners, and was ImmunoGen’s research lead on Genentech’s trastuzumab emtansine (T-DM1) program.
Bob earned his PhD in Biochemistry at Brandeis University and was a research and postdoctoral fellow at the Eleanor Roosevelt Institute in Colorado.
David Weinstock received his medical degree from George Washington University School of Medicine in 1997. He subsequently completed his residency in Internal Medicine at New York Hospital/Cornell, and his fellowship in Medical Oncology and Infectious Diseases at Memorial Sloan-Kettering Cancer Center. He joined the staff of Dana-Farber Cancer Institute and Brigham and Women’s Hospital in 2008, where he is a medical oncologist and laboratory investigator in Hematologic Neoplasia. His research focuses on the relationship between DNA repair and the development of hematologic neoplasms.
Dr Weinstock has authored over 100 peer-reviewed manuscripts and book chapters on topics ranging from cancer pathogenesis to infections among immunocompromised hosts to mechanisms of DNA damage response.
Cornelia Baumgartner has over 18 years of clinical research experience working in the pharmaceutical industry, medical device industry and at the University Hospital in Basel. Her initial training was in nursing, and throughout her career she has completed different research specific courses. In 2012 she successfully completed a Diploma of Advanced Studies in Clinical Research Practice and Management at the University of Basel.
David Browning has over 24 years of clinical drug development experience working in the pharmaceutical industry, contract research organization (CRO) and academic settings. While at the NCI-designated Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center, he oversaw the daily operations of the Clinical Trials Office, which was responsible for over 175 oncology trials and 13 INDs, and has directly managed over 30 phase I through III clinical trials worldwide from research through drug approval.
Press return to search